Shorter- vs. longer-course antibiotics in children with acute uncomplicated UTIs: a systematic review and meta-analyses.

Clin Microbiol InfectMay 7, 2026 (epub)
Clinical ResearchPediatricsInfectious Diseases

Ming Liu, Qi Wang, PeiJing Yan et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of shorter-course (2-5 days) versus longer-course (≥7 days) antibiotic therapy in 2010 children with acute uncomplicated urinary tract infections (UTIs). The findings suggest that shorter-course therapy likely results in no significant difference in relapse rates (RR 1.08) and reinfection rates (RR 0.63) compared to longer courses.

Key findings

  • Shorter-course therapy shows no significant difference in relapse rates (RR 1.08).
  • Reinfection rates are lower with shorter-course therapy (RR 0.63).
  • No significant difference in adverse events between shorter and longer courses (RR 0.93).
  • Bacteriological and clinical cure rates show little or no difference with shorter courses.

Why it matters

Understanding the effectiveness of shorter antibiotic courses can help clinicians optimize treatment for pediatric patients with UTIs, potentially reducing antibiotic exposure and associated side effects without compromising outcomes.

Source

PubMed · PMID 42106001

Published in Clin Microbiol Infect. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.